H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating

Innoviva, Inc. (NASDAQ:INVA) is one of the best small cap stocks to buy with huge upside potential. Innoviva, Inc. (NASDAQ:INVA) received a rating update from H.C. Wainwright on December 16, who lifted the price target to $46 from $45 while keeping a Buy rating on the stock.

The rating update came after Innoviva, Inc. (NASDAQ:INVA) reported the FDA approval of NUZOLVENCE® (zoliflodacin) on December 12, with the firm telling investors that zoliflodacin’s approval came on schedule. Zoliflodacin is a first-in-class, single-dose, oral antibiotic to treat uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg.

NUZOLVENCE’s development was a part of a not-for-profit, private collaboration with the The Global Antibiotic Research and Development Partnership (GARDP), which led and sponsored the Phase 3 clinical trial.

Innoviva, Inc. (NASDAQ:INVA) reported that the FDA approval was based on the results from this Phase 3 clinical trial, which was the largest ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five countries. The approval makes NUZOLVENCE one of the first new FDA-approved treatments for the condition in nearly two decades.

Innoviva, Inc. (NASDAQ:INVA) is involved in the development, commercialization, and financial management of biopharmaceuticals.

While we acknowledge the potential of INVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.